2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10871
    Otenabant 686344-29-6 99.63%
    Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.
    Otenabant
  • HY-11077
    SR 146131 221671-61-0 98.23%
    SR 146131 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist.
    SR 146131
  • HY-40136
    cis-4-Hydroxy-L-proline 618-27-9 ≥98.0%
    cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension.
    cis-4-Hydroxy-L-proline
  • HY-B0848
    Tricyclazole 41814-78-2 98.64%
    Tricyclazole is a pentaketone melanin biosynthesis inhibitor and a unique fungicide for controlling rice blast. Tricyclazole alters the structure and function of fungal cell walls, reduces fungal pathogenicity and penetration, and causes dose-dependent liver damage in animals.
    Tricyclazole
  • HY-N0341
    Scopolin 531-44-2 99.65%
    Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots. Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades.
    Scopolin
  • HY-N0458
    Pedunculoside 42719-32-4 99.75%
    Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation.
    Pedunculoside
  • HY-N0657
    Pinoresinol Diglucoside 63902-38-5 99.84%
    Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.
    Pinoresinol Diglucoside
  • HY-N0660
    Jujuboside B 55466-05-2 99.92%
    Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway. Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
    Jujuboside B
  • HY-N0712
    Typhaneoside 104472-68-6 99.74%
    Typhaneoside is an orally active activator of PI3K/Akt/mTOR and farnesoid X receptor. Typhaneoside promotes the activation of AMPK and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside can be used in research related to heart failure after myocardial infarction, acute myeloid leukemia, non-alcoholic fatty liver disease and neurological disorders.
    Typhaneoside
  • HY-N0818
    Chikusetsusaponin Iva 51415-02-2 99.61%
    Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a KD value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects.
    Chikusetsusaponin Iva
  • HY-N1354
    Reynoutrin 549-32-6
    Reynoutrin (Quercetin-3-D-xyloside) is a flavonoid from Psidium cattleianum, with antioxidant and radical-scavenging activity.
    Reynoutrin
  • HY-N1984
    Artemisic acid 80286-58-4 99.62%
    Artemisinic acid (Qing Hao acid) is a sesquiterpene that can be isolated from Artemisia annua L. Artemisinic acid is also an important precursor for the synthesis of Artemisinin (HY-B0094). Artemisinic acid has various pharmacological activities, such as antimalarial activity, antitumor activity, antipyretic effect, antibacterial activity, allelopathic effect, and anti-adipogenic effect.
    Artemisic acid
  • HY-P1064
    Apelin-36(human) 252642-12-9 98.01%
    Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
    Apelin-36(human)
  • HY-P2535
    GLP-1 (7-36), amide, biotin labeled 1802086-70-9 98.36%
    Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.
    GLP-1 (7-36), amide, biotin labeled
  • HY-Y0504
    Trimethylammonium chloride 593-81-7 98.0%
    Trimethylammonium chloride (Hegzadesil) is a non-competitive Acetylcholinesterase inhibitor. Trimethylammonium chloride reversibly blocks the deacetylation of acetylcholinesterase.
    Trimethylammonium chloride
  • HY-Y1422
    Triacylglycerol lipase 9001-62-1
    Triacylglycerol lipase is an enzyme catalyzing the hydrolysis of triacylglycerol. Triacylglycerol lipase promotes fat decomposition, providing energy and lipid precursors for cells. Triacylglycerol lipase is used in the research of metabolic diseases such as diabetes and obesity.
    Triacylglycerol lipase
  • HY-101082
    N6,2′-O-Dimethyladenosine 57817-83-1 99.93%
    N6,2′-O-Dimethyladenosine is a FTO substrate and reversible RNA modification. N6,2′-O-Dimethyladenosine acts as a demethylation substrate for FTO, which removes its methyl groups. N6,2′-O-Dimethyladenosine correlates with enhanced mRNA stability, improved translation efficiency and increased protein expression levels. N6,2′-O-Dimethyladenosine is applicable to research related to obesity and colorectal cancer.
    N6,2′-O-Dimethyladenosine
  • HY-103151
    CP94253 hydrochloride 845861-39-4 98.00%
    CP94253 hydrochloride is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 hydrochloride induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 hydrochloride can be used for the research of depression and heightened aggressive behavior.
    CP94253 hydrochloride
  • HY-106019
    Liarozole 115575-11-6 98.96%
    Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties.
    Liarozole
  • HY-113098
    2-Oxovaleric acid 1821-02-9
    2-Oxovaleric acid is an analog of Pyruvate and a substrate inhibitor of Lactate dehydrogenase, exhibiting substrate inhibitory activity against lactate dehydrogenase from Phycomyces blakesleeanus.
    2-Oxovaleric acid
Cat. No. Product Name / Synonyms Application Reactivity